Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,…
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group…
Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment…
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM…
New York, NY, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The soft launch of iCare ABA Therapy is drawing attention across…
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Truelli, a pioneering healthtech startup, is advancing its research and development on the…
Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire…
Global Healthcare Startups Invited to Apply for 12-Week Program with Mentorship, Investor Exposure, and Pitch Competition NEW YORK, Sept. 18,…
Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to…